StockNews.AI
TMDX
StockNews.AI
179 days

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit - TMDX

1. TMDX faces a class action lawsuit alleging securities fraud. 2. Allegations include kickbacks, fraudulent overbilling, and unsafe practices. 3. Affected investors can claim compensation for losses incurred. 4. Heightened regulatory scrutiny and investor risk are central concerns.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit raises concerns over corporate governance and legal exposure, likely triggering short-term sell-offs. Similar past cases in biotech and healthcare have led to notable quick price declines amid legal uncertainties.

How important is it?

The direct involvement of TMDX in a significant class action lawsuit increases market uncertainty and investor risk, making this news highly relevant for near-term price movement.

Why Short Term?

Legal actions usually cause immediate market volatility, while long-term fundamentals remain less affected. Historical examples show that class action lawsuits impact short-term sentiment more than long-term business viability.

Related Companies

TMDX
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=130878&wire=4 TMDX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. WHAT'S NEXT? If you suffered a loss in TransMedics during the relevant time frame, you have until April 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News